[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.145.218.90. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
July 1988

Intravitreal Clearance of Tissue Plasminogen Activator in the Rabbit

Author Affiliations

From the Departments of Ophthalmology (Drs Jaffe, Hartz, and Williams and Mr McKay) and Biostatistics (Dr Hartz), Medical College of Wisconsin, Milwaukee; and Invitron Corp, St Louis (Dr Green).

Arch Ophthalmol. 1988;106(7):969-972. doi:10.1001/archopht.1988.01060140115036
Abstract

• The clearance of tissue plasminogen activator (t-PA) injected into the midvitreous cavity was studied in the phakic, vitrectomized rabbit eye with and without intravitreal fibrin clots. The quantity and activity of t-PA in the vitreous, serum, and aqueous were determined at ten minutes and at 3, 6, 15, 24, and 48 hours after initial injection by an enzyme-linked immunosorbent assay (ELISA) and a spectrophotometric solid-phase fibrin assay (SOFIA). In eyes without an intravitreal fibrin clot, the estimated half-life for t-PA was 4.3 hours by SOFIA and 5.8 hours by ELISA. In eyes containing a vitreal fibrin clot, the half-life increased to 9.8 hours by SOFIA and 11.9 hours by ELISA. Both of these half-lives were significantly greater than the half-life for eyes without fibrin. Regardless of the presence of fibrin, intravitreal t-PA activity was significantly less than t-PA quantity, suggesting the presence of a t-PA inhibitor. A peak in aqueous t-PA occurred before six hours, indicating that t-PA was cleared in part through the anterior chamber. There was no measurable serum t-PA at any of the sampling times.

References
1.
Lambrou FH, Snyder RW, Williams GA:  Treatment of experimental intravitreal fibrin with tissue plasminogen activator . Am J Ophthalmol 1987;104:619-623.
2.
Abel R Jr, Boyle GL:  Dissecting ocular tissue for intraocular drug studies . Invest Ophthalmol 1976;13:216-219.
3.
Cano-Angles E:  A spectrophotometric solid phase fibrin-tissue plasminogen activator activity assay (SOFIA-t-PA) for high-fibrin-affinity tissue plasminogen activators . Anal Biochem 1986;153:201-210.Article
4.
Doft BH, Weiskopf J, Nilsson-Ehle J, et al:  Amphotericin clearance in vitrectomized versus nonvitrectomized eyes . Ophthalmology 1985;92:1601-1605.Article
5.
Scholes GN, O'Brien WJ, Abrams GW, et al:  Clearance of triamcinolone from vitreous . Arch Ophthalmol 1985;103:1567-1569.Article
6.
Cobo LM, Forster RK:  The clearance of intravitreal gentamicin . Am J Ophthalmol 1981;92:59-62.
7.
Pflugfelder SC, Hernández E, Fliesler SJ, et al:  Intravitreal vancomycin: Retinal toxicity, clearance, and interaction with gentamicin . Arch Ophthalmol 1987;105:831-837.Article
8.
Maurice DM:  Injection of drugs into the vitreous body , in Leopold J, Burns R (eds): Symposium on Ocular Therapy , New York, John Wiley & Sons Inc, 1976, pp 59-71.
9.
Dano K, Andreasen PA, Grondahl-Hansen J, et al:  Plasminogen activators, tissue degradation, and cancer . Adv Cancer Res 1985;44:150-266.
10.
Hoal EG, Wilson EL, Dowdle EB:  The regulation of tissue plasminogen activator activity by human fibroblasts . Cell 1983;34:273-279.Article
11.
Verstraete M, Collen D:  Thrombolytic therapy of the eighties . Blood 1986;67:1529-1541.
12.
Sebestyen JG:  Fibrinoid syndrome: A severe complication of vitrectomy surgery in diabetes . Ann Ophthalmol 1982;14:853-856.
13.
Aaberg TM, Williams GA:  Surgery of the vitreous and retina , in Sears MC, Tarkanen A (eds): Surgical Pharmacology of the Eye , New York, Raven Press, pp 503-521.
×